Business
Kintara Therapeutics to Present at the 2023 BIO CEO & Investor Conference
SAN DIEGO, Jan. 30, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the
About this update from Tuhura Biosciences, Inc.
[{"type":"text","content":"SAN DIEGO, Jan. 30, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) (\"Kintara\" or the \"Company\"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that Robert E. Hoffman, President and CEO of Kintara, will be presenting at the BIO CEO & Investor Conference on Monday, February 6, 2023.\nMr. Hoffman's presentation will highlight the recent Company developments on its novel therapies for hard to treat cancers, ongoing pipeline progress, clinical trial updates, and anticipated milestones. Details about the presentation are as follows:\nPresenter: Robert E. Hoffman, President and CEO of KintaraDate: Monday, February 6, 2023, at 4:30 p.m. ESTLocation: Marriott Marquis, New York, NYRegistration: Here\nIn its 25th year, BIO CEO is one of the largest investor conferences in the life science industry. Kintara will be available for in person and virtual partnering meetings. Those interested in scheduling a meeting may do so through the BIO One-on-One Partnering system: https://www.bio.org/events/bio-ceo-investor-digital-conference/partnering.\nABOUT KINTARA\nLocated in San Diego, California, Kintara is dedicated to the development of novel cancer therapies for patients with unmet medical needs. Kintara is developing two late-stage therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for glioblastoma (GBM) and REM-001 Therapy for cutaneous metastatic breast cancer (CMBC).\nVAL-083 is a 'first-in-class', small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including central nervous system, ovarian and other solid tumors (e.g., NSCLC, bladder cancer, head and neck) in U.S. clinical trials sponsored by the National Cancer Institute (NCI). Based on Kintara's internal research programs and these prior NCI-sponsored clinical studies, Kintara is currently advancing VAL-083 in the Global Coalition for Adaptive Research registrational Phase 2/3 clinical trial titled Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE) Study to support the development and commercialization of VAL-083 in GBM.\nKintara also has a proprietary, late-stage photodynamic therapy platform that holds promise as a localized cutaneous, or viscer...